NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Incyte Corporation (INCY) Stock Analysis

Incyte Corporation (INCY) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

INCY

$126.75

−$1.25 (−0.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INCY with… →

INCY Key Statistics

As of Sep 4, 2026
Trading
Open
$126.46
Previous Close
$128.00
Day's Range
126.04–128.08
52-Week Range
81.09–132.60
Volume
1.03M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.77
Valuation
Market Cap
$25.69B
P/E Ratio
16.31
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.26
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
10.74
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.41
EPS (ttm)Profit attributable to each share over the last twelve months.
7.77
Financials (FY)
Revenue (FY)
$5.14B+21.22%
Net Income (FY)
$1.29B+3844.96%
Profit marginThe share of revenue left as profit after all costs and taxes.
27.71%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
202.70M
1-Year Return
+48.35%
Dividend and dates
Earnings Date
October 27, 2026estimated
Avg Volume
1.80M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INCY Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+28.33%
2025+43.00%
2024+10.00%
2023−21.83%
2022+9.43%
2021−15.61%
2020−0.39%
2019+37.32%
2018−32.86%
2017−5.55%
2016 (partial year)+13.89%

As of September 4, 2026.

INCY Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.14B$1.29B25.0%
2024$4.24B$32.62M0.8%
2023$3.70B$597.60M16.2%
2022$3.39B$340.66M10.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.14B$4.77B$1.34B$1.29B25.0%
2024$4.24B$3.93B$101.29M$32.62M0.8%
2023$3.70B$3.44B$655.36M$597.60M16.2%
2022$3.39B$3.19B$591.63M$340.66M10.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

INCY Valuation vs Biotechnology Median

Median of 656 stocks
MetricINCYBiotechnology medianvs median
P/E16.3112.5730% above
P/S ratio4.4115.260.3x the median
Profit margin27.71%0.00%27.7 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Incyte Corporation (INCY) is capitalised at $25.69B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2,844.

Over the past 52 weeks the price has ranged from $81.09 to $132.60. The most recent close on file for INCY is $126.75, dated September 4, 2026. That is −$1.25 (−0.98%) against the previous close. The latest close sits 56.31% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $5.14B. That is +21.22% against the prior fiscal year, when revenue was $4.24B. Net income for the same year was $1.29B. That is +3,844.96% against the prior fiscal year. The reported profit margin is 27.71%. That is 27.7 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 7.77.

Across the 4 fiscal years on file, revenue moves from $3.39B in 2022 to $5.14B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

INCY trades at a trailing price-to-earnings ratio of 16.31. That is 29.75% above the Biotechnology median of 12.57. The forward P/E on file is 14.26. The PEG ratio, which sets the P/E against expected earnings growth, reads 10.74. Measured against sales, the shares trade at 4.41 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +48.35%. Measured over 10 years, that is +4.45% a year compounded. The reported beta is 0.77. Annualized volatility over the trailing 10 years is 34.25%.

Growth & Income

No dividend is on file for INCY.

So far in 2026 the price is +28.33%. The strongest complete calendar year on file is 2025 at +43.00%; the weakest is 2018 at −32.86%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Incyte Corporation (INCY) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Incyte Corporation INCY $25.69B 16.3
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Incyte Corporation trades at a P/E of 16.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Visit website →